Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Zusätzlich bieten wir Ihnen UBE2C Antikörper (140) und UBE2C Proteine (25) und viele weitere Produktgruppen zu diesem Protein an.
Showing 5 out of 18 products:
UBE2C is involved in the anti-proliferative and pro-apoptotic functions of ECRG4 in esophageal squamous cell carcinoma.
loss of BRCA1 function results in an increase in UBE2C expression and chemical resistance to doxorubicin in breast cancer cells.
FoxM1 promotes glioma progression by enhancing UBE2C transcription
SAG/RBX2 E3 ligase complexes with UBCH10 and UBE2S ubiquitin-conjugating enzymes to ubiquitylate beta-TrCP1 via K11-linkage for degradation.
UBE2C and HOXA1 RNA and protein are differentially expressed in conventional and Spitz nevi and melanoma.
High UBE2C expression is associated with esophageal squamous cell carcinoma.
Urinary UBE2C cell-free RNA may be a valuable diagnostic marker for bladder cancer.
A role was identified for UBE2C as a marker of the androgen signaling pathway in prostate cancer.
Data suggest that the activity of AURKA might be regulated by UBE2C through regulating the activity of anaphasepromoting complex. UBE2C may be a new marker in the diagnosis of gastric cancer and may be a potential therapeutic target for the treatment of gastric adenocarcinoma.
High UBCH10 expression is associated with bortezomib-resistance in multiple myeloma.
the expression of UbcH10 in colorectal cancer samples as compared with healthy tissue sample from the same patient according to age at surgery, was examined.
UbcH10 may promote gastric cancer growth.
Identification of UBE2C as a target of wild-type and GOF mutant p53 further highlights the contribution of p53 in regulation of spindle assembly checkpoint
The anaphase-promoting complex/cyclosome C activity in human cells is tuned by the combinatorial use of three E2 ubiquitin-conjugating enzymes, namely UBE2C, UBE2S, and UBE2D.
Study shows an overexpression of UbcH10 mRNA and protein in the vast majority of colorectal cancer (CRC) patients analyzed and indicates that UbcH10 expression regulates CRC growth.
the present study showed that miR-196a promoted cell proliferation by targeting UBE2C in breast cancer. Thus, miR-196a may be a potential oncogene in breast cancer and a promising therapeutic target in breast cancer treatment.
UBE2C could regulate phospho-ERK1/2 level.
Data suggest that ubiquitin-conjugating enzyme UbcH10 may be a promising target for the therapy of breast cancer.
Upregulation of miR-17/20a promotes gastric cancer cell growth by targeting UBE2C.
UbcH10 overexpression increases carcinogenesis and blocks ALLN susceptibility in colorectal cancer.
alongside their canonical function in protein degradation, Ube2C and -S also control the extrusion of the first polar body.
results identify UbcH10 as a prominent protooncogene that causes whole chromosome instability and tumor formation over a wide gradient of overexpression levels
These results indicated that ubiquitination of certain factors by UBE2S and UBE2C plays a role in the escape from metaphase II arrest in porcine oocytes.
The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes, or E1s, ubiquitin-conjugating enzymes, or E2s, and ubiquitin-protein ligases, or E3s. This gene encodes a member of the E2 ubiquitin-conjugating enzyme family. This enzyme is required for the destruction of mitotic cyclins and for cell cycle progression. Multiple transcript variants encoding different isoforms have been found for this gene.
ubiquitin-conjugating enzyme E2C
, ubiquitin carrier protein C
, ubiquitin-protein ligase C
, cyclin-selective ubiquitin carrier protein
, mitotic-specific ubiquitin-conjugating enzyme
, ubiquitin-conjugating enzyme E2 C